

GATANGA INDUSTRIES LIMITED – Pioneering industry for Purple tea development in Kenya

TRANSFORMING CLINICAL OUTCOMES ON CRITICAL ELEMENTS – THE PURPLE TEA ADVANTAGES

The clinical trials are delineated for designing the transformation of clinical outcomes with the Purple Tea derivatives

FEBRUARY 6, 2022

NAIROBI

Dr. Debasish Banerjee – PhD – Strategy and Chartered Engineer CEO and Executive Director at Blackstone Synergy

Clinical Expert and Lead on the supervision and assessment fidelity of the clinical trils with Purple Tea derivatives

Dr. Aditi Bishnu – MS – Obstetrics and Gynecology with cutting edge surgical experiences on cancerous procedures

Chairman of the Board at Gatanga Industries and Tea Factory Ltd, Gatanga – for spearheading the business proposition for the Purple Tea derivatives and Innovations therein Dr. Kinyanjui



A. ABSTRACT ON KEY PURPLE TEA DERIVATIVES

The power of relevant food polymers in the right concentration for cleansing the blood chemistry and provide holistic healing of various critical aspects of the blood related diseases like DM (diabetes mellitus) – both Type-1 and Type -2, cholesterol triggered cardiac complications and the cardio-pulmonary oppressive distresses cannot be underestimated. Cancerous patients on terminal conditions undergoing the palliative therapies related to chemotherapeutic treatment protocols and the concomitant radiation maintenance cohorts can particularly benefit from the feeds of appropriate food polymers.

Purple tea is one of the rare species that is grown in Kenya and nowhere else in the world. Purple tea has the highest concentration of properties that are relevant for palliative maintenance therapies for a wide cross-section of patients at various stages of the prognosis.

Gatanga Industries Tea Factory Limited have been at the forefront in developing specialty teas as a cottage industry with a network of tea scientists, food technologists and engineers.

The features of the innovations in Purple tea entail the creation of a proprietary activation energy threshold that is designed to shift the kinetic equilibrium to the third order reaction states of the polymerization process and allow the richness of the critical components of the tea to concentrate on the sap and enable higher order diffusion and keeping properties in the liquor.

The advantages of the Purple tea are chronicled in the illustrative chart that showcases the properties of various teas grown in either the highlands or the plains of Kenya and much of the tea growing world.

The findings as illustrated in the chart are self-explanatory in narrating the superior properties of Purple tea.



PURPLE TEA COHORT - THE DYNAMICS OF CLINICAL CHANGES - STRUCTURAL CORRELATIONSHIPS ON A HYPOTHETICAL BEDROCK

ANTI - OXIDANTS AS FOOD POLYMERIC CHAINS	ELEMENTS	Gatanga ITF Ltd	Generic industry - Kenya	Generic industry - India and the tea growing world	IMPACT RATING - Metabolism - Blood, muscle and glucose	IMPACT RATING - Blood Chemistry triggered compromise on cardio-pulmonary functional profiling	IMPACT RATING - Neurological functionality and qualitative blood perfusion in the CNS (by clinical deduction)
	Flavonoids	High	Medium	Medium	High sensitivity	Extremely high sensitivity	Major clinical breakthroughs expected for Stages - I - III disorders and with significant improvements in clinical prognosis for an extended life

Blackstone Synergy Consulting Group

plains

					. ()
VFC - volatile flavor compounds	High	High - highlands / Medium - plains	High - highlands / Medium - plains	High sensitivity	Extremely high sensitivity
SFC - stable flavor compounds	High	Low - highlands / Negligible - plains	Low - highlands / Negligible - plains	High sensitivity	Extremely high sensitivity
Catcheins - enzymated	High	Medium - highlands / negligible - plains	Medium - highlands / negligible - plains	High sensitivity	Extremely high sensitivity
Catcheins - oxidized	High	High - highlands / Medium -	High - highlands / Medium -	High sensitivity	Extremely high sensitivity

span of > 9-12 months for Stage -

IV patients

Creating the turnaround algorithm

plains



Key Notes on Gatanga Innovation


- 1. The activation energy is engineered to trigger the priority weaning off of chiral bonds for the free radicals from the parent organic compounds of the proteins and the carbohydrates. The reaction proceeds too termination for the first order reaction wherein the sap has the concentration of free radicals that create a dielectric field of high flux strength.
- 2. The distribution of engineered air on the tea substrates prevents the premature prevention of the kinetic equilibrium at the juxtaposed coordinates of the first and second orders of reaction as in generic withering processes globally followed by the sundry manufacturers across the tea growing countries.
- 3. In the Gatanga Innovation model, the second order reaction promotes the polymerization of the amino acids and the sugars to constitute the VFC volatile flavor compounds that are primarily oligomers or weak monomers and polymers susceptible to being weaned off from the surface. The VFCs are the first of favor compounds that actually have medicinal properties in improving on the blood metabolism.
- 4. The third order reaction promotes the kinetic equilibrium to terminate at coordinates that are significantly displaced thereby leading to the formation of cross linking polymeric chains of protein sugar combines and the simultaneous enzymatic fermentation as well as oxidation of the catcheins to bring forth the aromas and the keeping properties
- 5. The graphical analysis of the kinetic equilibrium differences between the conventional and Gatanga innovations are illustrated here under. The coordinates of the equilibrium shift substantially with the incorporation of the Gatanga technologies thereby assisting in achieving better flavors et al.



MICROSTRUCTURAL CHANGES IN PROGRESSION OF CONCENTRATION AT THE WITHERING INTERFACE

	I			<u></u>	
	GATANGA WITHERING	<u> 3</u>	CONVENTIONA	CONVENTIONAL WITHERING	
REACTION ORDER	PARENT PROTEIN COMPOUND - Gatanga	AMINO ACID - Gatanga	PARENT PROTEIN COMPOUND - conventional	AMINO ACID - conventional	
	0.97	0.03	0.97	0.03	
FIRST ORDER	0.92	0.08	0.85	0.15	
REACTION	0.88	0.12	0.62	0.38	
	0.63	0.37	0.58	0.42	
	0.58	0.42	0.51	0.49	
SECOND	0.57	0.43	0.51	0.49	
ORDER REACTION	0.53	0.47	0.51	0.49	
	0.51	0.49	0.51	0.49	
	0.41	0.59	0.51	0.49	
	0.37	0.63	0.51	0.49	
THIRD	0.33	0.67	0.51	0.49	
ORDER	0.31	0.69	0.51	0.49	
REACTION	0.27	0.73	0.51	0.49	
	0.25	0.75	0.51	0.49	

Blackstone Synergy Consulting Group
"transforming lives through business excellence"





B. DESCRIPTION OF THE CLINICAL PARAMETERS THAT ARE SOUGHT TO BE CORRELATED WITH THE PURPLE TEA DERIVATIVES OF THE GATANGA INNOVATION

B.1. Metabolic factors – blood, glucose and muscle

7 – point critical indicators of the metabolic factors are:

- 1. Blood metabolic indicators HD lipids and triglyceride levels- these are the first and second indicators
- 2. Glucose metabolic indicators Creatinine and serum insulin these are the third and fourth critical indicators in the metabolism grid.
- 3. Muscle metabolic indicators HCT%, Diastolic systolic gap and Serum protein concentration these are the fifth, sixth and seventh critical indicators in the metabolism grid.

B.2. Cardio – pulmonary influences having the following 7-point critical indicators:

- 1. Blood profile Hb% and TPC these are the first and the second critical indicators in the cardio-pulmonary grid
- 2. Cardio-pulmonary data V/Q pulmonary, aminolysis data, O2/Co2 partial pressure data, O2 concentration and Co2 concentration data these are the five critical elements of the cardio-pulmonary functionality.

B.3. CNS grid for influences on thoracic organ failures:

- 1. Electromechanical states of the CNS NCV tests, TSH levels, cognitive insights analytical assessment tests, Neuro motor coordination tests and the CBV cerebral blood volume these are the five critical indicators of the CNS
- 2. MRI induced blood perfusion deductive tests V/Q CNS and DSC- dynamic susceptibility tests for deriving the cell opacity percentage in the CNS.



C. THE TEST PROTOCOLS

The tests shall be conducted on clinical population of the target group that shall be administered uniformly with 2L of Purple tea over 24 hours, the control group of patients that have near similar or almost identical symptoms and the placebo group who are made aware of the purported benefits of purple tea but are administered with normal tea offered as purple tea.

The sample size shall be statistically significant to eliminate the anomalies and errors in interpretation of clinical data.

D. STATISTICAL INTERPRETATION OF DATA AND CONCLUSIVE INFERENCES

- 1. R² analysis of trending data from the clinical trials to establish close fitting dynamics and deduced reliability of the conclusions being drawn thereof.
- 2. Normalization of the data scatter to compare between the placebo, target and the control populace vis-à-vis the initial scatter to establish statistically significant gains for conclusive evidence wherever pertinent in the mentioned classes of clinical analyses.
- 3. Stablishing the critical elements that do significantly change with the administration of purple tea.
- 4. Psycho-somatic analysis of the degrees of proximity between the placebo and the target data to reasonably draw inferences on the fidelity of the treatment protocols of the Purple Tea efficacy for the elements seen to demonstrate changes that are reproducible and tangible.
- 5. To publish the findings once established unambiguously.

Purple Tea innovations of Gatanga Industries Tea Factory Limited are directed for sustainable changes in the treatment of cancer, diabetes and cardio-pulmonary complications for posterity.

This is an initiative to reach out to the humanity.